CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale CHIEF OPERATING OFFICER sold 260 shares at $25.06 ($6,515)
- 4 Planned sale CHIEF OPERATING OFFICER sold 4,875 shares at $22.72 ($110,769)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 1,000 shares at $22.50 ($22,500)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,000 shares at an average $17.92 ($214,988)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $16.97 ($55,165)
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- 4 Planned sale PRESIDENT AND CEO sold 12,000 shares at $16.89 ($202,700)
- CORRESP Other Correspondence Between Filers and SEC Staff
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- UPLOAD Other SEC-generated Letter
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-3 Offering Registration Statement
- SC 13D/A Stake Beneficial Ownership Report
- 4 Planned sale CHIEF OPERATING OFFICER sold 17,500 shares at $25.03 ($438,099)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 30,000 shares at $25.04 ($751,332)
Page 20 of 40 · 798 filings